83 citations
,
October 2016 in “Stem Cells and Development” This study found that epidermal growth factor significantly enhances the proliferation of hair follicle-derived mesenchymal stem cells through the EGFR/ERK and AKT pathways, without involving the STAT3 pathway.
18 citations
,
January 2017 in “Postępy Dermatologii i Alergologii” This review discusses the adverse skin effects of EGFR inhibitors used in cancer treatment, exploring their mechanisms and offering strategies for prevention and management, but reports no new experimental findings.
July 2022 in “British Journal of Dermatology” This study found that epidermal growth factor receptor inhibitors used in cancer treatment induce a distinct inflammatory response in hair follicles, marked by immune privilege collapse and upregulation of inflammatory pathways.
169 citations
,
September 2002 in “British journal of dermatology/British journal of dermatology, Supplement” This study reports that ZD1839 (Iressa), an anticancer drug, was associated with acneiform eruptions and hair growth abnormalities due to its inhibition of epidermal growth factor receptor signaling in the skin.
32 citations
,
January 2010 in “Journal of Dermatological Science” In this study, Waved-5 mice with reduced EGFR signaling showed nearly normal skin and hair follicle function but experienced a transient reduction in subcutaneous fat.
20 citations
,
July 2013 in “PLoS ONE” This study found that inhibiting EGFR signaling in mice can prevent alopecia caused by cyclophosphamide treatment, highlighting its potential role in managing chemotherapy-induced hair loss.
13 citations
,
December 2005 in “Traffic” In this study, researchers found that syntaxin 9, a novel syntaxin family member, interacts specifically with the epidermal growth factor receptor and may influence its transport and signaling in some epithelial cells.
25 citations
,
September 2018 in “Molecular Biology of the Cell” This study found that in mice lacking EGFR, elevated Wnt signaling disrupts hair follicle development by affecting cell proliferation and differentiation, revealing a critical role for EGFR in regulating these processes.
82 citations
,
May 2009 in “Development” This study found that downregulation of EGF and KGF signaling is necessary for hair follicle initiation in placodes, revealing a new role for KGF in hair follicle formation in mice.
November 2022 in “Journal of Investigative Dermatology” This study implicates EGFR as a critical regulator of immune privilege and stem cell quiescence in hair follicles, suggesting a link between EGFR inhibition and inflammation-driven hair loss during cancer therapy.
57 citations
,
August 2006 in “Journal of the American Academy of Dermatology” This case report describes a woman who developed extensive nonscarring inflammatory hair loss after two years of gefitinib treatment, highlighting potential cutaneous side effects associated with epidermal growth factor receptor blockers.
97 citations
,
June 2013 in “Journal of Dermatological Science” This review discusses the role of the EGF receptor/ligand system in skin homeostasis and its implications for keratinocyte stem cells and reports no new clinical results.
1 citations
,
June 2023 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” This study found that deleting the vitamin D receptor from specific stem cells in mouse hair follicles disrupts their ability to regenerate the epidermis after injury, suggesting an essential interaction with the transcription factor p63.
13 citations
,
February 2018 in “Plastic and Reconstructive Surgery” The study found that a specific signaling pathway helps skin wounds heal faster but may lead to larger scars.
10 citations
,
July 2019 in “Advances in Wound Care” This study suggests that Flightless I may inhibit the activation of epidermal stem cells during wound repair by disrupting Wnt/β-catenin signaling, potentially delaying wound reepithelialization.
19 citations
,
September 2008 in “Journal of Cellular Physiology” This article explores potential mechanisms of acneiform skin eruptions linked to EGFR inhibition in cancer patients, focusing on EGFR's role in controlling IL-1-dependent inflammation at hair follicles, but reports no clinical results.
114 citations
,
July 2003 in “PubMed” This study found that KSR1 is necessary for v-Ha-ras-mediated skin tumor formation but not for MT-driven mammary cancer, indicating its potential as a therapeutic target in Ras/MAPK signaling-related tumors.
23 citations
,
June 2012 in “Molecular Biology Reports” This study found that human outer root sheath cells express VEGF receptor-2, and exogenous VEGF165 significantly stimulates their proliferation through activation of the ERK signaling pathway.
1 citations
,
November 2023 in “iScience” In this study, researchers found that disrupting desmoglein 3 signaling in a mouse model of pemphigus vulgaris activates normally quiescent hair follicle stem cells, compromising their multipotency but prompting a regenerative response that restores stem cell function and structures.
1 citations
,
January 2022 in “BMC Genomic Data” In this study, researchers found that androgen receptor activation in dermal papilla cells mainly affected the focal adhesion pathway and downregulated caveolin-1 gene expression, which could help identify new therapeutic targets for testosterone-related diseases.
February 2026 in “Biomedicine & Pharmacotherapy” In this study, researchers developed EPO-derived peptides that enhanced hair growth by stimulating dermal papilla cells and increasing IGF-1 expression without triggering systemic erythropoietic effects in tested models, indicating a promising approach for treating hair loss.
April 2019 in “Journal of Investigative Dermatology” This study developed an Asian human sebocyte cell line from breast skin tissue that can be used for sebaceous gland biology investigations, showing that Y27632 may promote cell growth through EGFR-CRAF-MEK-ERK and AKT pathways.
116 citations
,
December 2003 in “Acta Dermato Venereologica” This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.
39 citations
,
March 2009 in “Dermatology Online Journal” This paper discusses the role of epidermal growth factor receptor blockade in altering skin and hair growth, highlighting hair growth stimulation as a potential side effect of cancer therapy; it reports no new experimental results.
1 citations
,
December 2023 in “Animals” In this study, researchers observed that the skin quality and hair follicle development of Rex rabbits improved when slaughtered in winter compared to summer, with findings suggesting seasonal regulation via multiple signaling pathways affecting fur characteristics.
March 2009 in “Dermatology Online Journal” This study reports that blocking the epidermal growth factor receptor in cancer treatments can lead to changes in hair growth and create a "wavy" hair phenotype in some patients.
122 citations
,
June 1998 in “PubMed” This study found that sensory and sympathetic innervation in the mystacial pads of mice is governed by a balance of neurotrophin signaling, highlighting the roles of NGF/trkA and NT-3/trkC pathways.
9 citations
,
January 2017 in “Elsevier eBooks” This chapter discusses the skin stem cell niche as a complex ecosystem and highlights the diverse components and interactions that influence stem cell function, but it reports no new experimental results.
1 citations
,
April 2024 in “Journal of Cutaneous Pathology” This article presents a case of spontaneous, recurrent necrotizing infundibular crystalline folliculitis in the inguinal region and suggests unknown etiology possibly linked to microbiome and sebaceous gland dysfunction.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” This study explores how EGFR signaling impacts skin inflammation and follicular integrity during hair eruption, aiming to identify druggable pathways to mitigate skin inflammation in cancer patients receiving EGFR inhibitors.